SG&A Efficiency Analysis: Comparing Pfizer Inc. and MannKind Corporation

SG&A Efficiency: A Tale of Two Companies

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This analysis compares the SG&A efficiency of Pfizer Inc. and MannKind Corporation from 2014 to 2023.

Pfizer Inc.: A Model of Consistency

Pfizer, a global pharmaceutical giant, consistently maintained high SG&A expenses, averaging around $14 billion annually. Despite fluctuations, Pfizer's expenses remained relatively stable, reflecting its robust operational scale and market presence.

MannKind Corporation: Navigating Challenges

In contrast, MannKind Corporation, a smaller player, exhibited more volatility. Its SG&A expenses ranged from $47 million to $108 million, highlighting the challenges faced by smaller firms in managing operational costs.

Key Insights

Over the decade, Pfizer's SG&A expenses were approximately 200 times higher than MannKind's, underscoring the disparity in scale and market strategy between the two companies.